Knowing stock market today at a glance

Edwards Lifesciences (EW) Shares Soar 6.63% on Strong Q1 Earnings

Mover TrackerThursday, Apr 24, 2025 6:33 pm ET

1min read

Edwards Lifesciences (EW) shares surged 6.63%, reaching their highest level since February 2025, with an intraday gain of 8.27%.

Edwards Lifesciences' strong Q1 financial performance played a significant role in the stock's recent surge. The company reported a 6.2% increase in sales, reaching $1.41 billion, driven by a 58% rise in TMTT sales due to robust global demand. This impressive performance led the company to raise its 2025 revenue forecast, instilling confidence among investors.

Analysts have also shown optimism towards Edwards Lifesciences. Piper Sandler upgraded the company's stock from Neutral to Overweight, while Stifel maintained a Buy rating with a price target of $90.00. These upgrades reflect the positive outlook on the company's future prospects.

Additionally, the FDA's approval of a key product boosted market optimism, contributing to the stock's increase. Despite potential challenges from tariffs and the acquisition of JenaValve, Edwards Lifesciences has maintained its full-year financial forecasts, projecting sales growth to offset these costs. This resilience has been appreciated by analysts, further supporting the stock's upward trajectory.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.